P.2.044 Clozapine, norclozapine plasma levels during a long term treatment of schizophrenic patients

1997 ◽  
Vol 7 ◽  
pp. S207
Author(s):  
M.C. Mauri ◽  
S. Bravin ◽  
Ricci ◽  
L. Boscati ◽  
E. Giuliani ◽  
...  
1978 ◽  
Vol 16 (14) ◽  
pp. 55-56

Neuroleptic drugs cause many forms of extra-pyramidal syndromes. One of these, tardive dyskinesia,1 occurs only after the patient has been taking the drug for some time (‘tardive’ refers to the late onset). The movements are involuntary and repetitive usually involving the face and tongue, but they may also affect the limbs and trunk. Tongue protrusion, licking and smacking of the lips, sucking and chewing movements, grimacing, grunting, blinking and furrowing of the forehead have all been described and attributed to long-continued medication with neuroleptic drugs of the phenothiazine, butyrophenone and thioxanthene groups. The patient can inhibit the movements, but anxiety makes them worse. Many of these symptoms were noticed in schizophrenic patients before neuroleptic drugs were introduced2 and they can occur in otherwise normal untreated elderly people. Nevertheless it is generally accepted that in most cases tardive dyskinesia is an unwanted effect of neuroleptic medication. Despite suggestions to the contrary, the abnormal movements are not necessarily associated with high dosage of neuroleptic drugs or with pre-existing brain damage.3 4 Tardive dyskinesia has been reported in 3–6% of a mixed population of psychiatric patients5 and over half of a group of chronic schizophrenics on long-term treatment.4 The more careful the neurological examination, the greater the apparent incidence.


2021 ◽  
Vol 33 (4) ◽  
pp. 747-755
Author(s):  
Tomoe Ozeki ◽  
Tetsuya Mouri ◽  
Hiroko Sugiura ◽  
Yuu Yano ◽  
Kunie Miyosawa ◽  
...  

Medication is a key treatment for patients with schizophrenia. Patients with schizophrenia tend to easily decrease medication adherence with long-term treatment. However, there is a chronic shortage of specialists who provide medication support, such as visiting nurses. In addition, these patients do not often use smartphones or PCs in their daily lives. Thus, schizophrenic patients need a direct approach in the physical world because they are unfamiliar with cyberspace. This study aims to improve the home treatment environment using robot technology that can approach in the physical world of schizophrenic patients who need medication support. In this study, collaboration between psychiatric nursing specialists and medical engineers investigated the interaction between communication robots and patients. The results showed that the robot was accepted by patients with schizophrenia as a talking partner. The amount of robot talking seemed to affect the impression of the robot on schizophrenics. Utterance process analysis showed that the smoothness of the conversation affected the relationship between robots and schizophrenics.


1984 ◽  
Vol 54 (8) ◽  
pp. 1008-1014 ◽  
Author(s):  
Franco Naccarella ◽  
Daniele Bracchetti ◽  
Massimo Palmieri ◽  
Bruno Marchesini ◽  
Ettore Ambrosioni

2011 ◽  
Vol 26 (S2) ◽  
pp. 1789-1789
Author(s):  
H.-J. Moeller

Schizophrenia is a chronic disorder with a high risk of poor outcome in terms of symptoms and social functioning and possibly also progressive brain alterations. The relapse rate is high and each relapse can induce further aggravations, both in psychosocial as well as in neurobiological terms. Thus, acute and long-term treatment with the highest degree of effectiveness should be provided to the patients in acute and long-term treatment.Neuroleptic medication is the most important part of the treatment regimen for schizophrenic patients. The efficacy of neuroleptics in the acute and long-term treatment of schizophrenia is very well proven and the effect size is comparatively high. The second-generation antipsychotics (SGAs) have advantages over the neuroleptics of the first-generation (FGAs), and high expectations have therefore been put into them for the treatment of schizophrenia. Their better extrapyramidal-motor tolerability and efficacy in treating negative, depressive and cognitive symptoms, in addition to positive symptoms, supposedly result in a more favourable influencing of the overall course of the disease and in a higher quality of life for the patients, thus improving their acceptance by patients and leading to increased compliance. Differences in the pharmacological profile can be identified among others by receptor imaging approaches.


2007 ◽  
Vol 41 (12) ◽  
pp. 997-1004 ◽  
Author(s):  
Xiang Yang Zhang ◽  
Yun Long Tan ◽  
Dong Feng Zhou ◽  
Lian Yuan Cao ◽  
Gui Ying Wu ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document